Sangart Completes Enrollment In Phase III Study Of Its Novel Blood Substitute Hemospan

Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of blood substitutes, announced that it has completed enrollment in a Phase III trial of its lead product Hemospan(R).